← Research ProtocolsRetatrutide
STUDIED EXPOSURE MAP / 2023
Retatrutide
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / RANDOMIZED PHASE 2NEW ENGLAND JOURNAL OF MEDICINESTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
1 mg
once weekly · SC
4 mg
once weekly · SC · initial-dose variants used
8 mg
once weekly · SC · initial-dose variants used
12 mg
once weekly · SC
Context: The trial used multiple randomized target-dose groups and different initial-dose strategies in some arms. The figures shown are study exposures, not a titration recommendation.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / NEW ENGLAND JOURNAL OF MEDICINE
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2023
01 / DESIGNPhase 2 · double-blind · randomized · placebo-controlled
02 / POPULATION / MODELAdults with obesity, or overweight plus at least one weight-related condition
03 / ROUTESubcutaneous · once weekly
04 / TIMEFRAME48 weeks
05 / PRIMARY QUESTIONPercentage change in body weight from baseline
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
GLP-1, GIP and glucagon receptor research
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.